A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing
Fig 4
Drug-protein interaction after docking.
A. 3CLPro-Darifenacin interaction, B. 3CLPro-Nebivolol interaction, C. NSP10-Alvimopan interaction, and D. NSP10-Isbesartan interaction. Drugs are in orange while the proteins are labelled in blue and the residues interacting with the drugs are highlighted in red. The contacts are shown in yellow.